Holen Sie sich die Stockscreener-App
1.38
12.66%
-0.20
Handel nachbörslich:
1.40
0.02
+1.45%
Schlusskurs vom Vortag:
$1.58
Offen:
$1.55
24-Stunden-Volumen:
196.38K
Relative Volume:
8.70
Marktkapitalisierung:
$30.34M
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-181.41M
KGV:
-2.8163
EPS:
-0.49
Netto-Cashflow:
$-68.18M
1W Leistung:
-36.70%
1M Leistung:
-53.54%
6M Leistung:
-54.46%
1J Leistung:
-36.99%
1-Tages-Spanne:
$1.30
$1.6253
1-Wochen-Bereich:
$1.30
$2.21
52-Wochen-Spanne:
$1.30
$7.97
Celularity Inc Stock (CELU) Company Profile
Firmenname
Celularity Inc
Sektor
Branche
Telefon
(908) 768-2170
Adresse
170 PARK AVE, FLORHAM PARK
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-30 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-04-06 | Herabstufung | Truist | Buy → Hold |
| 2022-01-28 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-24 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Celularity Inc Aktie (CELU) Neueste Nachrichten
CELU stock touches 52-week low at $1.55 amid market fluctuations - Investing.com India
Celularity reports over $24 million in biomaterial revenue By Investing.com - Investing.com Australia
Celularity Inc. Announces Anticipated Revenues for Second and Third Quarters - Defense World
Celularity reports over $24 million in biomaterial revenue - Investing.com India
Celularity Receives Nasdaq Delisting Notice Over Filing Delay - Marketscreener.com
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel - The Manila Times
Celularity reports progress on Nasdaq compliance and product sales - Investing.com
Celularity reports progress on Nasdaq compliance and product sales By Investing.com - Investing.com Australia
Celularity Provides Corporate Update - citybiz
CELUWCelularity Inc. Warrant Latest Stock News & Market Updates - StockTitan
Celularity faces Nasdaq delisting over reporting delays - Investing.com
Celularity faces Nasdaq delisting over reporting delays By Investing.com - Investing.com UK
Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal - ForexTV.com
Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc. - The Manila Times
Celularity expands biomaterials range with Rebound acquisition - Investing.com India
Celularity Inc SEC 10-Q Report - TradingView
Celularity (NASDAQ:CELU) Stock Price Down 8.8%Should You Sell? - MarketBeat
Amniotic Membrane Market to Grow by USD 2.7 Billion (2024-2028) with AI Impact Boosting Trends in Ophthalmic Surgery UseTechnavio Report - The Malaysian Reserve
BTIG maintains Buy rating on Cullinan Oncology stock - Investing.com
Cullinan Oncology maintains Buy rating from H.C. Wainwright with steady price target - Investing.com India
Trend Tracker for (CLS) - Stock Traders Daily
Cullinan Therapeutics (NASDAQ:CGEM) Earns Outperform Rating from Wedbush - MarketBeat
Caesars Entertainment Inc (CZR) stock: A year of ups and downs - US Post News
In the Green: Cerus Corp. (CERS) Closes at 1.97, Up/Down -4.37 from Previous Day - The Dwinnex
Creo Medical to get £25m boost from majority sale of its European business - Business Live
Medical device company to sell stake of subsidiary to Chinese manufacturerequity value of €72m - Insider Media
Objective long/short (CGEM) Report - Stock Traders Daily
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA - Yahoo Finance
Cullinan Therapeutics Inc (CGEM)’s stock price in review: A technical analysis - US Post News
(CELC) Technical Pivots with Risk Controls - Stock Traders Daily
Creo Medical Partners with Micro-Tech for Strategic Growth - TipRanks
E Fund Management Co. Ltd. Purchases New Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
State of New Jersey Common Pension Fund D Has $3.31 Million Stock Holdings in Caesars Entertainment, Inc. (NASDAQ:CZR) - Defense World
Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com - MarketBeat
Cullinan Therapeutics commences Phase 1 trial for lupus treatment By Investing.com - Investing.com Canada
Celcuity Inc. (NASDAQ:CELC) Short Interest Update - MarketBeat
Capricor shares gain as Oppenheimer raises price target to $15 - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 5.5% - MarketBeat
Certara (NASDAQ:CERT) Shares Up 5% - MarketBeat
How Is The Market Feeling About Celestica? - Benzinga
Should You Increase Your Holdings in Certara (CERT)? - Insider Monkey
Centerra Gold shares target raised on molybdenum unit outlook - Investing.com India
Views of Wall Street’s Leading Experts on Centerra Gold Inc. - SETE News
Centuri Holdings, Inc. (NYSE:CTRI) Short Interest Update - Defense World
Caesars Entertainment Inc’s latest rating changes from various analysts - Knox Daily
Celadon Pharmaceuticals Expands Share Capital - TipRanks
Certara (NASDAQ:CERT) Sees Strong Trading Volume - MarketBeat
Is Caesars Entertainment, Inc. (NASDAQ:CZR) the Best Las Vegas Stock To Buy Now? - Yahoo Finance
Analyzing Ratios: Cullinan Therapeutics Inc (CGEM)’s Financial Story Unveiled - The Dwinnex
Cullinan Oncology's stock gets buy rating after trial data - Investing.com
Does Cerus Corp. (CERS) offer a good opportunity for investors? - SETE News
Finanzdaten der Celularity Inc-Aktie (CELU)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.11%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):